{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:01:33Z","timestamp":1779379293432,"version":"3.53.1"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s00415-022-11241-5","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T12:03:34Z","timestamp":1657541014000},"page":"5674-5681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Contemporary management challenges in seropositive NMOSD"],"prefix":"10.1007","volume":"269","author":[{"given":"Fiona","family":"Costello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie M.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"11241_CR1","unstructured":"Costello F (2023) Neuromyelitis optica spectrum disorders (NMOSD): optimizing diagnosis and management. Continuum (Minneap Minn) (in press)"},{"issue":"3","key":"11241_CR2","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/WCO.0000000000000694","volume":"32","author":"K Fujihara","year":"2019","unstructured":"Fujihara K (2019) Neuromyelitis optica spectrum disorders: still evolving and broadening. Curr Opin Neurol 32(3):385\u2013394","journal-title":"Curr Opin Neurol"},{"key":"11241_CR3","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1759-1961.2012.00030.x","volume":"3","author":"K Fujihara","year":"2012","unstructured":"Fujihara K, Misu T, Nakashima I et al (2012) Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3:58\u201373","journal-title":"Clin Exp Neuroimmunol"},{"key":"11241_CR4","doi-asserted-by":"publisher","first-page":"501","DOI":"10.3389\/fneur.2020.00501","volume":"11","author":"JY Hor","year":"2020","unstructured":"Hor JY, Asgari N, Nakashima I et al (2020) Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide. Front Neurol 11:501. https:\/\/doi.org\/10.3389\/fneur.2020.00501","journal-title":"Front Neurol"},{"key":"11241_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1212\/WNL.0000000000011153","volume":"96","author":"V Papp","year":"2021","unstructured":"Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P (2021) Worldwide incidence and prevalence of neuromyelitis optica. Neurology 96:59\u201377. https:\/\/doi.org\/10.1212\/WNL.0000000000011153","journal-title":"Neurology"},{"issue":"2","key":"11241_CR6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","volume":"85","author":"DM Wingerchuk","year":"2015","unstructured":"Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85(2):177\u2013189","journal-title":"Neurology"},{"key":"11241_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/jmsard.202.102522","volume":"46","author":"X Ma","year":"2020","unstructured":"Ma X, Kermode AG, Hu X, Qui W (2020) Risk of relapse in patients with neuromyelitis optica spectrum disorder: recognition and preventive strategy. Mult Scler Relat Disord 46:102522. https:\/\/doi.org\/10.1016\/jmsard.202.102522","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"11241_CR8","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1093\/brain\/awz054","volume":"142","author":"J Palace","year":"2019","unstructured":"Palace J, Lin DY, Zeng D et al (2019) Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders. Brain 142(5):1310\u20131323","journal-title":"Brain"},{"key":"11241_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102750","volume":"49","author":"Y Takai","year":"2021","unstructured":"Takai Y, Kuroda H, Misu T, Akaishia T, Nakashima I, Takahashi T et al (2021) Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord 49:102750","journal-title":"Mult Scler Relat Disord"},{"key":"11241_CR10","doi-asserted-by":"publisher","first-page":"932","DOI":"10.3389\/fneur.2020.00932","volume":"11","author":"T Akaishi","year":"2020","unstructured":"Akaishi T, Takeshita T, Himori T et al (2020) Rapid administration of high-dose intravenous methylprednisolone improves visual outcomes after optic neuritis in patients with AQP4-IgG-positive NMOSD. Front Neurol 11:932. https:\/\/doi.org\/10.3389\/fneur.2020.00932","journal-title":"Front Neurol"},{"key":"11241_CR11","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000504","volume":"6","author":"I Kleiter","year":"2018","unstructured":"Kleiter I, Gahlen A, Borisow N et al (2018) Apheresis therapies for NMOSD attacks A retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 6:e504","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"11241_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10257-z","author":"S Siritho","year":"2020","unstructured":"Siritho S, Nopsopon T, Pongpirul K (2020) Therapeutic plasma exchange vs conventional treatment with intravenous high dose steroid for neuromyelitis optica spectrum disorders (NMOSD): a systematic review and meta-analysis. J Neurol. https:\/\/doi.org\/10.1007\/s00415-020-10257-z","journal-title":"J Neurol"},{"key":"11241_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.msard.2018.12.010","volume":"28","author":"A Banerjee","year":"2019","unstructured":"Banerjee A, Ng J, Coleman J, Ospina JP, Mealy M, Levy M (2019) Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment. Mult Scler Relat Disord 28:60\u201363. https:\/\/doi.org\/10.1016\/j.msard.2018.12.010","journal-title":"Mult Scler Relat Disord"},{"key":"11241_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10352-1","author":"L DeLott","year":"2021","unstructured":"DeLott L, Bennett JL, Costello F (2021) The changing landscape of optic neuritis: a narrative review. J Neurology. https:\/\/doi.org\/10.1007\/s00415-020-10352-1","journal-title":"J Neurology"},{"issue":"3","key":"11241_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/jca.21705","volume":"34","author":"A Padmanabhan","year":"2019","unstructured":"Padmanabhan A, Connelly-Smith L, Aqui N et al (2019) Guidelines on the use of therapeutic apheresis in clinical practice\u2014evidence-based approach from the Writing Committee of the American Society of Apheresis: the eighth special issue. J Clin Apher 34(3):171\u2013354","journal-title":"J Clin Apher"},{"key":"11241_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/WNO.0000000000000700","volume":"38","author":"L Horton","year":"2018","unstructured":"Horton L, Bennett JL (2018) Acute management of optic neuritis and evolving paradigm. J Neuroophthalmol 38:358\u2013367. https:\/\/doi.org\/10.1097\/WNO.0000000000000700","journal-title":"J Neuroophthalmol"},{"key":"11241_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102709","volume":"48","author":"Z Huang","year":"2021","unstructured":"Huang Z, Wu J, Xiao Y, Zhang Z (2021) Timing of plasma exchange for neuromyelitis optical spectrum disorders: a meta-analysis. Mult Scler Relat Disord 48:102709","journal-title":"Mult Scler Relat Disord"},{"key":"11241_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102325","volume":"44","author":"X Li","year":"2020","unstructured":"Li X, Tian DC, Fan M et al (2020) Intravenous immunoglobulin for acute attacks in neuromyelitis optical spectrum disorders (NMOSD). Mult Scler Relat Disord 44:102325","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"11241_CR19","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1177\/1352458513495938","volume":"20","author":"L Elsone","year":"2014","unstructured":"Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, Jacob A (2014) Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 20(4):501\u2013504. https:\/\/doi.org\/10.1177\/1352458513495938","journal-title":"Mult Scler"},{"key":"11241_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4103\/1735-1995.200275","volume":"22","author":"M Etemadifar","year":"2017","unstructured":"Etemadifar M, Salari M, Mirmosayyeb O et al (2017) Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci 22:18","journal-title":"J Res Med Sci"},{"issue":"6","key":"11241_CR21","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1017\/cjn.2017.201","volume":"44","author":"LJ Baxter","year":"2017","unstructured":"Baxter LJ, Chen S, Couillard P, Scott JN, Doig C, Costello F, Girard LP, Klassen J, Burton JM (2017) Refractory longitudinally extensive transverse myelitis responsive to cyclophosphamide. Can J Neurol Sci 44(6):736\u2013739","journal-title":"Can J Neurol Sci"},{"issue":"11","key":"11241_CR22","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","volume":"73","author":"V Damato","year":"2016","unstructured":"Damato V, Evoli A, Iorio R (2016) Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 73(11):1342\u20131348","journal-title":"JAMA Neurol"},{"key":"11241_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12883-019-1261-2","volume":"19","author":"F Gao","year":"2019","unstructured":"Gao F, Chai B, Gu C et al (2019) Effectiveness of rituximab in neuromyelitis optica: a meta-analysis. BMC Neurol 19:36","journal-title":"BMC Neurol"},{"issue":"3","key":"11241_CR24","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","volume":"71","author":"MA Mealy","year":"2014","unstructured":"Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71(3):324\u2013330","journal-title":"JAMA Neurol"},{"issue":"1","key":"11241_CR25","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","volume":"20","author":"M Levy","year":"2021","unstructured":"Levy M, Fujihara K, Palace J (2021) New therapies for neuromyelitis optica spectrum disorder. Lancet Neurol 20(1):60\u201367","journal-title":"Lancet Neurol"},{"key":"11241_CR26","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1056\/NEJMoa1900866","volume":"381","author":"SJ Pittock","year":"2019","unstructured":"Pittock SJ, Berthele A, Fujihara K et al (2019) Eculizumab in aquaporin-4 positive neuromyelitis optica spectrum disorder. N Engl J Med 381:614\u2013625","journal-title":"N Engl J Med"},{"issue":"5","key":"11241_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","volume":"19","author":"A Traboulsee","year":"2020","unstructured":"Traboulsee A, Greenberg BM, Bennett JL et al (2020) Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, doubleblind, multicentre, placebocontrolled phase 3 trial. Lancet Neurol 19(5):402\u2013412","journal-title":"Lancet Neurol"},{"key":"11241_CR28","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","volume":"381","author":"T Yamamura","year":"2019","unstructured":"Yamamura T, Kleiter I, Fujihara K et al (2019) Trial of satralizumab in neuromyelitis optica spectrum disorder. N Engl J Med 381:2114\u20132124","journal-title":"N Engl J Med"},{"issue":"10206","key":"11241_CR29","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","volume":"394","author":"BAC Cree","year":"2019","unstructured":"Cree BAC, Bennett JL, Kim HJ et al (2019) Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (NMOmentum): a double blind, randomised placebo controlled phase 2\/3 trial. Lancet 394(10206):1352\u20131363","journal-title":"Lancet"},{"issue":"5","key":"11241_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/acr2.11133","volume":"2","author":"ZS Wallace","year":"2020","unstructured":"Wallace ZS, Harkness T, Blumenthal KG, Choi HK, Stone JH, Walensky RP (2020) Increasing operational capacity and reducing costs of rituximab administration: a costing analysis. ACR Open Rheumatol 2(5):261\u2013268. https:\/\/doi.org\/10.1002\/acr2.11133","journal-title":"ACR Open Rheumatol"},{"key":"11241_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102971","volume":"52","author":"SA Brod","year":"2021","unstructured":"Brod SA (2021) Immune reconstitution therapy in NMOSD. Mult Scler Relat Disord 52:102971. https:\/\/doi.org\/10.1016\/j.msard.2021.102971","journal-title":"Mult Scler Relat Disord"},{"key":"11241_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.102990","volume":"53","author":"JM Burton","year":"2021","unstructured":"Burton JM, Duggan P, Costello F, Metz L, Storek J (2021) A pilot trial of autologous hematopoietic stem cell transplant in neuromyelitis optic spectrum disorder. Mult Scler Relat Disord 53:102990. https:\/\/doi.org\/10.1016\/j.msard.2021.102990 (Epub 2021 May 4)","journal-title":"Mult Scler Relat Disord"},{"key":"11241_CR33","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40120-020-00200-947","volume":"9","author":"A Bertolotto","year":"2020","unstructured":"Bertolotto A, Martire S, Mirabile L et al (2020) Autologous hematopoietic stem cell transplantation (AHSCT): standard of care for relapsing-remitting multiple sclerosis patients. Neurol Ther 9:197\u2013203. https:\/\/doi.org\/10.1007\/s40120-020-00200-947","journal-title":"Neurol Ther"},{"key":"11241_CR34","unstructured":"Liest TP (2021) Toward Personalized Care for Multiple Sclerosis. https:\/\/practicalneurology.com\/articles\/2021-feb\/toward-personalized-care-for-multiple-sclerosis\/pdf. Accessed 6 Mar 2022"},{"key":"11241_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102538","volume":"46","author":"SA Brod","year":"2020","unstructured":"Brod SA (2020) Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord 46:102538","journal-title":"Mult Scler Relat Disord"},{"issue":"14","key":"11241_CR36","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","volume":"81","author":"Y Jiao","year":"2013","unstructured":"Jiao Y, Fryer JP, Lennon VA et al (2013) Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology 81(14):1197\u20131204","journal-title":"Neurology"},{"key":"11241_CR37","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1093\/brain\/aws109","volume":"135","author":"J Kitley","year":"2012","unstructured":"Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin 4 antibody patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834\u20131849","journal-title":"Brain"},{"issue":"4","key":"11241_CR38","doi-asserted-by":"publisher","first-page":"e727","DOI":"10.1212\/NXI.0000000000000727","volume":"7","author":"J Jitprapaikulsan","year":"2020","unstructured":"Jitprapaikulsan J, Fryer JP, Majed M et al (2020) Clinical utility of AQP4-IgG titers and measures of complement-mediated cell killing in NMOSD. Neurol Neuroimmunol Neuroinflamm 7(4):e727. https:\/\/doi.org\/10.1212\/NXI.0000000000000727","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"11241_CR39","first-page":"815","volume":"25","author":"E Flanagan","year":"2019","unstructured":"Flanagan E (2019) Neuromyelitis optica spectrum disorder and other non-multiple sclerosis central nervous system inflammatory diseases. Continuum (Minneap Minn) 25(3):815\u2013844","journal-title":"Continuum (Minneap Minn)"},{"key":"11241_CR40","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3389\/fneur.2018.00888","volume":"9","author":"N Borisow","year":"2018","unstructured":"Borisow N, Mori M, Kuwabara S, Scheel M, Paul F (2018) Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol 9:888","journal-title":"Front Neurol"},{"issue":"6","key":"11241_CR41","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","volume":"82","author":"DK Sato","year":"2014","unstructured":"Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474\u2013481","journal-title":"Neurology"},{"key":"11241_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.746959","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Tan G, Li B, Zhang J, Gao Y, Cao Y, Jia Z, Sugimoto K (2021) Serum aquaporin 4-immunoglobulin G titer and neuromyelitis optica spectrum disorder activity and severity: a systematic review and meta-analysis. Front Neurol 12:746959. https:\/\/doi.org\/10.3389\/fneur.2021.746959","journal-title":"Front Neurol"},{"issue":"410","key":"11241_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/jns.2020.116671","volume":"15","author":"T Akaishi","year":"2020","unstructured":"Akaishi T, Takahashi T, Nakashima I et al (2020) Repeated follow-up of AQP4-IgG titer by cell-based assay in neuromyelitis optica spectrum disorders (NMOSD). J Neurol Sci 15(410): https:\/\/doi.org\/10.1016\/jns.2020.116671","journal-title":"J Neurol Sci"},{"issue":"1","key":"11241_CR44","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12974-021-02138-7","volume":"18","author":"P Schindler","year":"2021","unstructured":"Schindler P, Ulrike Grittner U, Oechtering J et al (2021) Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. J Neuroinflammation 18(1):105. https:\/\/doi.org\/10.1186\/s12974-021-02138-7","journal-title":"J Neuroinflammation"},{"issue":"10","key":"11241_CR45","doi-asserted-by":"publisher","first-page":"2954","DOI":"10.1093\/brain\/awab241","volume":"144","author":"S Bittner","year":"2021","unstructured":"Bittner S, Oh J, Havrdova\u0301 E, Tintore\u0301 M, Zipp F (2021) The potential of serum neurofilament as biomarker for multiple sclerosis. Brain 144(10):2954\u20132963","journal-title":"Brain"},{"issue":"13","key":"11241_CR46","doi-asserted-by":"publisher","first-page":"e1299","DOI":"10.1212\/WNL.0000000000008160","volume":"93","author":"M Watanabe","year":"2019","unstructured":"Watanabe M, Nakamura Y, Michalak Z, Isobe N, Barro C, Leppert D et al (2019) Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 93(13):e1299\u2013e1311. https:\/\/doi.org\/10.1212\/WNL.0000000000008160","journal-title":"Neurology"},{"issue":"3","key":"11241_CR47","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000708","volume":"7","author":"H Kim","year":"2020","unstructured":"Kim H, Lee EJ, Kim S, Choi LK, Kim K, Kim HW et al (2020) Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease. Neurol Neuroimmunol Neuroinflamm 7(3): e708. https:\/\/doi.org\/10.1212\/NXI.0000000000000708","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"11241_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.647618","volume":"12","author":"X Chang","year":"2021","unstructured":"Chang X, Huang W, Wang L, ZhangBao J, Zhou L, Lu C et al (2021) Serum neurofilament light and GFAP are associated with disease severity in inflammatory disorders with aquaporin-4 or myelin oligodendrocyte glycoprotein antibodies. Front Immunol 12:647618. https:\/\/doi.org\/10.3389\/fimmu.2021.647618","journal-title":"Front Immunol"},{"issue":"5","key":"11241_CR49","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ana.26067","volume":"89","author":"O Aktas","year":"2021","unstructured":"Aktas O, Smith MA, Rees WA, Bennett JL, She D, Katz E et al (2021) Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker. Ann Neurol 89(5):895\u2013910. https:\/\/doi.org\/10.1002\/ana.26067","journal-title":"Ann Neurol"},{"issue":"4","key":"11241_CR50","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1177\/13524585211024978","volume":"28","author":"H Kim","year":"2022","unstructured":"Kim H, Lee EJ, Kim S, Choi LK, Kim HJ, Kim HW et al (2022) Longitudinal follow-up of serum biomarkers in patients with neuromyelitis optica spectrum disorder. Mult Scler 28(4):512\u2013521. https:\/\/doi.org\/10.1177\/13524585211024978","journal-title":"Mult Scler"},{"key":"11241_CR51","doi-asserted-by":"publisher","first-page":"175628642110143","DOI":"10.1177\/17562864211014389","volume":"14","author":"JM Solomon","year":"2021","unstructured":"Solomon JM, Paul F, Claudia Chien C, Oh J, Rotstein DL (2021) A window into the future? MRI for evaluation of neuromyelitis optica spectrum disorder throughout the disease course. Ther Adv Neurol Disord 14:17562864211014389. https:\/\/doi.org\/10.1177\/17562864211014389","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"11241_CR52","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000269","volume":"3","author":"RA Kessler","year":"2016","unstructured":"Kessler RA, Mealy MA, Levy M (2016) Early indicators of relapses vs pseudorelapses in neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm 3(5):e269. https:\/\/doi.org\/10.1212\/NXI.0000000000000269","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"11241_CR53","doi-asserted-by":"publisher","first-page":"E1057","DOI":"10.1212\/NXI.0000000000001057","volume":"8","author":"SD Newsome","year":"2021","unstructured":"Newsome SD, Cross AH, Fox RJ et al (2021) COVID-19 patients with neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody disease in north america from the COViMS registry. Neurol Neuroimmunol Neuroinflamm 8(5):E1057","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"11241_CR54","doi-asserted-by":"publisher","first-page":"e1060","DOI":"10.1212\/NXI.0000000000001060","volume":"8","author":"SL Apostolos-Pereira","year":"2021","unstructured":"Apostolos-Pereira SL, Campos Ferreira L, Boaventura M et al (2021) Clinical features of COVID-19 on patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 8(6):e1060. https:\/\/doi.org\/10.1212\/NXI.0000000000001060","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"11241_CR55","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1001\/jamaneurol.2021.0688","volume":"78","author":"A Salter","year":"2021","unstructured":"Salter A, Fox RJ, Newsome SD, Halper J et al (2021) Outcomes and risk factors associated with SARS-CoV-2 infection in a North American registry of patients with multiple sclerosis. JAMA Neuro 78(6):699\u2013708. https:\/\/doi.org\/10.1001\/jamaneurol.2021.0688","journal-title":"JAMA Neuro"},{"issue":"4","key":"11241_CR56","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/ana.26028","volume":"89","author":"MP Sormani","year":"2021","unstructured":"Sormani MP, De Rossi N, Schiavetti I et al (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol 89(4):780\u2013789. https:\/\/doi.org\/10.1002\/ana.26028","journal-title":"Ann Neurol"},{"key":"11241_CR57","doi-asserted-by":"publisher","first-page":"102474","DOI":"10.1016\/j.msard.2020.102474","volume":"46","author":"NS de Ruijter","year":"2020","unstructured":"de Ruijter NS, Kramer G, Gons RAR, Hengstman GJD (2020) Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: a case report. Mult Scler Relat Disord 46:102474. https:\/\/doi.org\/10.1016\/j.msard.2020.102474 (Epub 2020 Sep 1. PMID: 32892062; PMCID: PMC7462544)","journal-title":"Mult Scler Relat Disord"},{"key":"11241_CR58","doi-asserted-by":"publisher","first-page":"577439","DOI":"10.1016\/j.jneuroim.2020.577439","volume":"350","author":"R Ghosh","year":"2020","unstructured":"Ghosh R, De K, Roy D et al (2020) A case of area postrema variant of neuromyelitis optica spectrum disorder following SARS-CoV-2 infection. J Neuroimmunol 350:577439. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577439 (Epub ahead of print. PMID: 33333471; PMCID: PMC7657006)","journal-title":"J Neuroimmunol"},{"issue":"9","key":"11241_CR59","doi-asserted-by":"publisher","first-page":"e17961","DOI":"10.7759\/cureus.17961","volume":"13","author":"P Fujikawa","year":"2021","unstructured":"Fujikawa P, Shah FA, Braford M, Patel K, Madey J (2021) Neuromyelitis optica in a healthy female after severe acute respiratory syndrome coronavirus 2 mRNA-1273 vaccine. Cureus 13(9):e17961. https:\/\/doi.org\/10.7759\/cureus.17961 (PMID: 34660149; PMCID: PMC8516014)","journal-title":"Cureus"},{"issue":"1","key":"11241_CR60","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","volume":"13","author":"S Jarius","year":"2016","unstructured":"Jarius S, Ruprecht K, Kleiter I, in cooperation with the NeuromyelitisOptica Study Group (NEMOS) et al (2016) MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 13(1):280. https:\/\/doi.org\/10.1186\/s12974-016-0718-0 (PMID: 27793206; PMCID: PMC5086042)","journal-title":"J Neuroinflammation"},{"key":"11241_CR61","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.msard.2018.07.006","volume":"25","author":"Y Tong","year":"2018","unstructured":"Tong Y, Liu J, Yang T et al (2018) Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis. Mult Scler Relat Disord 25:61\u201365. https:\/\/doi.org\/10.1016\/j.msard.2018.07.006 (Epub 2018 Jul 6. PMID: 30048918)","journal-title":"Mult Scler Relat Disord"},{"issue":"16","key":"11241_CR62","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1212\/WNL.0b013e318250d812","volume":"78","author":"W Kim","year":"2012","unstructured":"Kim W, Kim SH, Nakashima I et al (2012) Influence of pregnancy on neuromyelitis optica spectrum disorder. Neurology 78(16):1264\u20131267. https:\/\/doi.org\/10.1212\/WNL.0b013e318250d812 (Epub 2012 Apr 4. PMID: 22491862)","journal-title":"Neurology"},{"issue":"14","key":"11241_CR63","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1177\/1352458517740215","volume":"23","author":"E Shosha","year":"2017","unstructured":"Shosha E, Pittock SJ, Flanagan E, Weinshenker BG (2017) Neuromyelitis optica spectrum disorders and pregnancy: interactions and management. Mult Scler 23(14):1808\u20131817. https:\/\/doi.org\/10.1177\/1352458517740215 (PMID: 29154728)","journal-title":"Mult Scler"},{"issue":"1","key":"11241_CR64","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","volume":"86","author":"MM Nour","year":"2016","unstructured":"Nour MM, Nakashima I, Coutinho E, Woodhall M, Sousa F, Revis J et al (2016) Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder. Neurology 86(1):79\u201387. https:\/\/doi.org\/10.1212\/WNL.0000000000002208","journal-title":"Neurology"},{"key":"11241_CR65","first-page":"813","volume":"21","author":"M De Falco","year":"2007","unstructured":"De Falco M, Cobellis L, Torella M et al (2007) Downregulation of aquaporin 4 in huma placenta throughout pregnancy. In Vivo 21:813\u2013817","journal-title":"In Vivo"},{"issue":"15","key":"11241_CR66","doi-asserted-by":"publisher","first-page":"e2006","DOI":"10.1212\/WNL.0000000000011744","volume":"96","author":"N Collongues","year":"2021","unstructured":"Collongues N, Alves Do Rego C, Bourre B, Biotti D et al (2021) Pregnancy in patients with AQP4-Ab, MOG-Ab, or double-negative neuromyelitis optica disorder. Neurology 96(15):e2006\u2013e2015","journal-title":"Neurology"},{"key":"11241_CR67","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.reprotox.2017.05.002","volume":"71","author":"FDO de Steenwinkel","year":"2017","unstructured":"de Steenwinkel FDO, Dolhain DO, Hazes RJEM et al (2017) Does prednisone use or disease activity in pregnant women with rheumatoid arthritis influence the body composition of their offspring? Reprod Toxicol 71:118\u2013123","journal-title":"Reprod Toxicol"},{"issue":"1","key":"11241_CR68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/gast.2003.50014","volume":"124","author":"A Francella","year":"2003","unstructured":"Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH (2003) The safety of 6- mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 124(1):9\u201317","journal-title":"Gastroenterology"},{"issue":"3","key":"11241_CR69","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1212\/NXI.0000000000000453","volume":"5","author":"G Das","year":"2018","unstructured":"Das G, Damotte V, Gelfand JM, Bevan C, Cree BAC, Do L, Green AJ, Hauser SL, Bove R (2018) Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm 5(3):e453. https:\/\/doi.org\/10.1212\/NXI.0000000000000453 (PMID: 29564373; PMCID: PMC5858951)","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"4","key":"11241_CR70","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s11940-021-00666-4","volume":"23","author":"KM Krysko","year":"2021","unstructured":"Krysko KM, Bove R, Dobson R, Jokubaitis V, Hellwig K (2021) Treatment of women with multiple sclerosis planning pregnancy. Curr Treat Options Neurol 23(4):11. https:\/\/doi.org\/10.1007\/s11940-021-00666-4 (Epub 2021 Mar 30. PMID: 33814892; PMCID: PMC8008016)","journal-title":"Curr Treat Options Neurol"},{"issue":"3","key":"11241_CR71","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","volume":"16","author":"Y Mao-Draayer","year":"2020","unstructured":"Mao-Draayer Y, Thiel S, Mills EA, Chitnis T, Fabian M, Katz Sand I, Leite MI, Jarius S, Hellwig K (2020) Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations. Nat Rev Neurol 16(3):154\u2013170. https:\/\/doi.org\/10.1038\/s41582-020-0313-y (Epub 2020 Feb 20 PMID: 32080393)","journal-title":"Nat Rev Neurol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11241-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11241-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11241-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:07:35Z","timestamp":1744204055000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11241-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["11241"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11241-5","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]},"assertion":[{"value":"14 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no known conflicts of interest with the content of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}